Literature DB >> 16962152

Lack of neutralizing antibody response to HIV-1 predisposes to superinfection.

Davey M Smith1, Matthew C Strain, Simon D W Frost, Satish K Pillai, Joseph K Wong, Terri Wrin, Yang Liu, Christos J Petropolous, Eric S Daar, Susan J Little, Douglas D Richman.   

Abstract

Occurrences of HIV-1 superinfection offer a unique opportunity to investigate the correlates of immune protection. Here we describe the neutralizing antibody responses of a cohort of recently infected individuals who were screened for HIV superinfection. Three individuals identified with HIV superinfection had less cross-protective and autologous neutralizing antibody response than their non-superinfected case-controls. Neutralizing antibody may be crucial in the protection against superinfection and may explain why superinfection has only been documented following recent infection or treatment interruption. These data have considerable implications for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16962152     DOI: 10.1016/j.virol.2006.08.009

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  53 in total

1.  Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Authors:  Rebecca L R Powell; Thompson Kinge; Phillipe N Nyambi
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

Review 2.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

4.  Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfection.

Authors:  Antoine Chaillon; Gabriel A Wagner; N Lance Hepler; Susan J Little; Sergei L Kosakovsky Pond; Gemma Caballero; Mary E Pacold; Pham Phung; Terri Wrin; Douglas D Richman; Joel O Wertheim; Davey M Smith
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

5.  Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response.

Authors:  Gabriel A Wagner; Elise Landais; Gemma Caballero; Pham Phung; Sergei L Kosakovsky Pond; Pascal Poignard; Douglas D Richman; Susan J Little; Davey M Smith
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

6.  Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing.

Authors:  Andrew D Redd; Aleisha Collinson-Streng; Craig Martens; Stacy Ricklefs; Caroline E Mullis; Jordyn Manucci; Aaron A R Tobian; Ethan J Selig; Oliver Laeyendecker; Nelson Sewankambo; Ronald H Gray; David Serwadda; Maria J Wawer; Stephen F Porcella; Thomas C Quinn
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

7.  Increased HIV-1 superinfection risk in carriers of specific human leukocyte antigen alleles.

Authors:  Jouni Vesa; Antoine Chaillon; Gabriel A Wagner; Christy M Anderson; Douglas D Richman; Davey M Smith; Susan J Little
Journal:  AIDS       Date:  2017-05-15       Impact factor: 4.177

8.  Herpes simplex virus 2 serostatus and viral loads of HIV-1 in blood and semen as risk factors for HIV transmission among men who have sex with men.

Authors:  David M Butler; Davey M Smith; Edward R Cachay; George K Hightower; Charles Thomas Nugent; Douglas D Richman; Susan J Little
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

9.  HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk?

Authors:  Mary S Campbell; Geoffrey S Gottlieb; Stephen E Hawes; David C Nickle; Kim G Wong; Wenjie Deng; Thomas M Lampinen; Nancy B Kiviat; James I Mullins
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.